Prognostic value of soluble urokinase-type plasminogen activator receptor in coronary artery disease: A meta-analysis.

ABSTRACT:

Background

A potential inflammatory biomarker, soluble urokinase-type plasminogen activator receptor (suPAR) has been utilized to assist the prognostic assessment of coronary artery disease (CAD) patients; however, outcomes have been inconsistent. The prognostic relevance of suPAR as a predictor of CAD patient adverse outcomes was therefore examined.

Methods

Research articles published as of 1 January 2022 were retrieved from PubMed, Embase, the Web of Science and the Cochrane Library. All-cause mortality, cardiovascular mortality and other major cardiovascular events (nonfatal myocardial infarction, heart failure or stroke) were analysed as a subset of relevant studies' results. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for each study. The broad E

SUBMITTER: Li Y 

PROVIDER: S-EPMC9787755 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature